Mezigdomide (CC-92480), a cereblon E3 ubiquitin ligase modulating drug (CELMoD), acts as a molecular glue. Mezigdomide shows high affinity to cereblon, resulting in potent antimyeloma activity.
性状
Solid
体外研究(In Vitro)
Mezigdomide is the second cereblon modulator. Mezigdomide-induced loss of Aiolos and Ikaros in cultures of PBMCs resulted in the activation of T cells and increased production of IL-2 and IFN-γ. Mezigdomide is effective in CC-5013, CC-4047, and CC-220-resistant cell lines. It exerts single-agent induction of apoptosis and exhibits remarkable synergy with NSC 34521. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Nooka AK, et al. Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. Cancer J. 2019 Jan/Feb;25(1):19-31.
溶解度数据
In Vitro: DMSO : 5 mg/mL (8.81 mM; ultrasonic and warming and heat to 60°C)配制储备液